Clinical Trial Update: A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Avutometinib alone versus combination with Defactinib in recurrent low-grade serous ovarian cancer, including KRAS-mutant and KRAS-wild…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low-grade Serous Ovarian Cancer
• Ovarian Cancer

Drugs mentioned

• Avutometinib (avutometinib)
• Defactinib (defactinib)

Snippet

Sponsor: Verastem, Inc. | Conditions: Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING